Ophthalmic Drugs; Data, Analysis and Forecasts to 2024

ReportsWeb.com adds “Ophthalmic Drugs; Data, Analysis and Forecasts to 2024” to its Store

Which ophthalmic drugs lead the market in 2013? Will the same drugs be as successful in 2018? How will this landscape change across the next 10 years? Which trial drugs are likely to make an impact? Only one report will tell you the answers. Simply by ordering and reading Publisher's new 'Ophthalmic Drugs; Data, Analysis and Forecasts to 2024' report, you can stay ahead of your competition. It really is that simple.

Publisher forecasts that the global ophthalmic drugs market will reach $9.7bn by 2024. The US market growth will be slow compared to other markets predominantly due to major drug patent expiry and generic erosion. For example;

Report Url @ http://www.reportsweb.com/ophthalmic-drugs-data-analysis-and-forecasts-to-2024

- Xalabrands from Pfizer used for treatment of Glaucoma expired in the US in March 2011.
- Azopt by Alcon used for treatment of Glaucoma expired in the US in October 2012.
- Lumigan by Allergan used for treatment of Glaucoma expired in the US in 2013.
- Restasis from Allergan used for treatment of Dry eye will expire in the US in May 2014.
- Travatan by Alcon used for treatment of Glaucoma will expire in the US in 2014.
- Combigan by Allergan used for treatment of Glaucoma will expire in the US in 2022.
- Lucentis from Novartis used for treatment of Retinal Disorder will expire in the US in June 2020.

Request for Sample: http://www.reportsweb.com/inquiry&RW0001274187/sample

Restasis by Allergan is the market-leading drug in the ophthalmic market with sales of $1bn across 2013. Will it be able to see off the competition for the next 5 years? The next 10 years? This report tells you. With an assessment of the leading markets, such as the US, and EU, Publisher examine how Germany and France are the largest EU markets and what % of the global market they make up. Which other countries contribute most? This report tells you in a concise, focused and easily accessible format.

But how will these country's markets develop? This report will tell you - TODAY

Global incidences of AMD, Glaucoma and Diabetic Retinopathy are all set to increase dramatically across the forecast period of 2014-2024; this will have the knock-on effect of driving sales of key drugs for treatment i.e. Lucentis and Eylea, as well as driving R&D. How much is being spent on R&D - and which drugs are likely to see a return? And how quickly?

Inquire for Discount: http://www.reportsweb.com/inquiry&RW0001274187/discount

Which new drugs will we see in the ophthalmic market across 2014-2024?
In December 2013 Santen announced that Ikervis (Ciclosporin / Cyclokat) was filed to the EMA, in doing so the EMA will begin its regulatory process. Diquas, which was launched in 2010 by Santen Pharma in Japan, China and other Asian markets, and despite US trials being unsuccessful, is expected to gain approval in the EU early in our forecast period.

Other key ophthalmic drugs currently under taking trials include;
- Sirolimus (By Santen, in Phase III US)
- Tafluprost/Timolol maleate (By Santen, filed for NDA)
- Catioprost (By Santen in Phase 2)

About Us:

ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers.

Contact Us:

Phone: +1-646-491-9876

Email Id: sales@reportsweb.com